Overview

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Status:
Withdrawn
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Merrimack Pharmaceuticals
Treatments:
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin